Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2019-06-14 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
2018年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2018 Annual General Meeting (AGM) of 哈药集团股份有限公司, dated June 15, 2019. It details the meeting attendance, voting results on various agenda items including the 2018 annual report, board and supervisory reports, audit work summary, financial budget, profit distribution, and amendments to the company charter. The document is a formal announcement of the voting results and resolutions passed at the AGM, including legal witness statements confirming the validity of the meeting and votes. The document length is 3912 characters, which is relatively short and focused on the meeting outcomes rather than the full annual report or detailed financial statements. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results from the AGM rather than presenting the full annual report or other detailed reports.
2019-06-14 Chinese
关于哈药总厂注射用头孢粉针制剂生产线项目建设的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the construction of a new production line project by 哈药集团股份有限公司. It details the investment amount, project scope, location, expected economic benefits, and associated risks. There is no financial data, quarterly or annual results, or management discussion of financial performance. The document is a formal announcement about a capital investment project, not a financial report or earnings release. It fits the category of Capital/Financing Update (CAP) as it informs about a significant investment and project funding plans.
2019-06-14 Chinese
八届二十一次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from 哈药集团股份有限公司 regarding approval of an investment project. It includes details of the board meeting, voting results, and references a related announcement on the stock exchange website. The content focuses on board decisions and project approval, not on financial results, audit, or regulatory filings. It is not a full report but a formal announcement of a board decision. Therefore, it fits best under Board/Management Information (MANG). The document length is short and specific to board resolutions, confirming this classification.
2019-06-14 Chinese
关于参加投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an online investor collective reception day event, where company executives will interact with investors and answer questions. It does not contain financial statements, detailed financial data, or formal report content. It is a public notice related to investor relations and communication rather than a formal report or filing. The document length is short (623 characters), and it is an announcement of an event rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-06-13 Chinese
2018年年度股东大会会议材料
AGM Information Classification · 95% confidence The document is titled as materials for the 2018 Annual General Meeting (AGM) of 哈药集团股份有限公司, dated June 14, 2019. It contains detailed agenda items including the 2018 annual report full text and summary, board of directors' work report, supervisory board report, independent directors' report, audit work summary and reappointment of the accounting firm, financial statements for 2018 and budget for 2019, profit distribution plan, and other corporate governance matters. The content is comprehensive and includes substantive financial data, management reports, audit summaries, and governance information. The document is clearly the meeting materials for the AGM, not just an announcement or a brief summary. Therefore, it fits the category of AGM Information (AGM-R) which includes presentations and materials shared during the Annual General Meeting. The document length (15,000 characters) and detailed content support this classification with high confidence.
2019-06-05 Chinese
关于控股股东哈药集团增资扩股事宜的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a capital increase and share expansion by the controlling shareholder of the company. It discusses the process of inviting investors, regulatory approvals, and potential changes in control. The text is relatively short (829 characters) and focuses on providing an update about financing activities rather than presenting detailed financial data or full reports. This fits the description of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP.
2019-05-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.